Tredje AP fonden Sells 16,252 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Tredje AP fonden trimmed its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 50.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 16,253 shares of the medical equipment provider's stock after selling 16,252 shares during the period. Tredje AP fonden's holdings in Zimmer Biomet were worth $1,717,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. CKW Financial Group raised its position in shares of Zimmer Biomet by 11.7% during the 4th quarter. CKW Financial Group now owns 955 shares of the medical equipment provider's stock valued at $101,000 after acquiring an additional 100 shares in the last quarter. FWG Holdings LLC raised its position in shares of Zimmer Biomet by 2.9% during the 3rd quarter. FWG Holdings LLC now owns 3,591 shares of the medical equipment provider's stock valued at $372,000 after acquiring an additional 101 shares in the last quarter. Romano Brothers AND Company raised its position in shares of Zimmer Biomet by 1.1% during the 4th quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider's stock valued at $1,000,000 after acquiring an additional 102 shares in the last quarter. Dorsey & Whitney Trust CO LLC increased its position in Zimmer Biomet by 2.3% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 4,594 shares of the medical equipment provider's stock worth $485,000 after buying an additional 102 shares during the period. Finally, M&T Bank Corp increased its position in Zimmer Biomet by 0.4% in the fourth quarter. M&T Bank Corp now owns 26,827 shares of the medical equipment provider's stock worth $2,834,000 after buying an additional 108 shares during the period. 88.89% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Zimmer Biomet Trading Up 0.0 %

Shares of NYSE:ZBH traded up $0.03 during midday trading on Wednesday, reaching $112.91. The company had a trading volume of 1,919,909 shares, compared to its average volume of 1,487,508. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. Zimmer Biomet Holdings, Inc. has a 1-year low of $97.69 and a 1-year high of $133.90. The firm has a market cap of $22.48 billion, a price-to-earnings ratio of 25.37, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04. The company has a fifty day simple moving average of $106.18 and a two-hundred day simple moving average of $106.88.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period last year, the business posted $2.20 earnings per share. Research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.85%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet's dividend payout ratio (DPR) is presently 21.57%.

Insider Transactions at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares of the company's stock, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.95% of the company's stock.

Analysts Set New Price Targets

ZBH has been the topic of several analyst reports. JMP Securities reaffirmed a "market outperform" rating and issued a $140.00 target price on shares of Zimmer Biomet in a research report on Friday, February 7th. Barclays dropped their target price on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating on the stock in a research report on Monday, February 10th. Raymond James lowered their price target on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. JPMorgan Chase & Co. raised Zimmer Biomet from a "neutral" rating to an "overweight" rating and raised their price target for the company from $125.00 to $128.00 in a report on Tuesday, December 17th. Finally, Royal Bank of Canada lowered their price target on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.